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Abstract 
Rationale: Unlike traditional biopsy, liquid biopsy, which is a largely non-invasive diagnostic and 
monitoring tool, can be performed more frequently to better track tumors and mutations over time 
and to validate the efficiency of a cancer treatment. Circulating tumor cells (CTCs) are considered 
promising liquid biopsy biomarkers; however, their use in clinical settings is limited by high costs and 
a low throughput of standard platforms for CTC enumeration and analysis. In this study, we used a 
label-free, high-throughput method for CTC isolation directly from whole blood of patients using a 
standalone, clinical setting-friendly platform.  
Methods: A CTC-based liquid biopsy approach was used to examine the efficacy of therapy and 
emergent drug resistance via longitudinal monitoring of CTC counts, DNA mutations, and 
single-cell-level gene expression in a prospective cohort of 40 patients with epidermal growth factor 
receptor (EGFR)-mutant non-small cell lung cancer. 
Results: The change ratio of the CTC counts was associated with tumor response, detected by CT 
scan, while the baseline CTC counts did not show association with progression-free survival or 
overall survival. We achieved a 100% concordance rate for the detection of EGFR mutation, 
including emergence of T790M, between tumor tissue and CTCs. More importantly, our data 
revealed the importance of the analysis of the epithelial/mesenchymal signature of individual 
pretreatment CTCs to predict drug responsiveness in patients. 
Conclusion: The fluid-assisted separation technology disc platform enables serial monitoring of 
CTC counts, DNA mutations, as well as unbiased molecular characterization of individual CTCs 
associated with tumor progression during targeted therapy. 
Key words: circulating tumor cells, single cell analysis, gene expression, EGFR mutation, non-small cell lung 
cancer 
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Introduction 
Lung cancer is the most common cause of 
cancer-related mortality in both men and women 
worldwide [1, 2]. Non-small cell lung cancer (NSCLC) 
accounts for 84% of all lung cancers, and despite 
improved diagnostic techniques, a great majority of 
patients with NSCLC present with advanced-stage 
tumors at diagnosis, and the 5-year relative survival 
rate is less than 20% [3]. Epidermal growth factor 
receptor (EGFR) mutations are found in 10–30% of 
patients with NSCLC, and targeted therapies, 
including EGFR-tyrosine kinase inhibitors (TKIs) can 
deliver significantly improved clinical outcomes, 
depending upon the type of mutation [4, 5]. As 
new-generation EGFR-TKIs (e.g. osimertinib) [6, 7] 
have been developed recently for patients who 
showed resistance to conventional EGFR-TKIs, 
frequent examination of the tumor susceptibility to 
EGFR-TKIs became very important. However, 
conventional tissue biopsy is invasive, and therefore, 
more facile and less invasive liquid biopsy methods, 
able to monitor the disease response to targeted 
therapy and track the emergence of drug resistance, 
could significantly aid in the clinical management of 
the disease. 
Among various circulating biomarkers, 
circulating tumor cells (CTCs) offer a unique 
opportunity to obtain information on live tumor cells 
at the DNA, RNA, and protein levels. Despite 
significant challenges associated with the extremely 
rare and heterogeneous characteristics of CTCs, recent 
technological advancements have allowed studying 
the prognostic value of CTCs, as well as monitoring 
and predicting the efficacy of therapy. To date, 
various platforms have been developed to isolate 
CTCs based on their biochemical or physical 
properties, such as the expression of epithelial cell 
adhesion molecule (EpCAM) or their size. 
Nevertheless, only the CellSearch™ system (Menarini 
Silicon Biosystems) is currently approved by the US 
Food and Drug Administration for the enumeration of 
CTCs in patients with metastatic colorectal [8], breast 
[9], and prostate [10] cancer. However, the prognostic 
value of CTCs remains controversial in NSCLC. 
Although many previous studies have demonstrated 
that patients with a higher number of CTCs have a 
poor clinical outcome [11-16], some studies have 
reported that baseline CTC counts had no significant 
correlation with the survival rate in patients with 
NSCLC [17, 18]. 
Previous immunoaffinity-based CTC enrichment 
methods using anti-EpCAM antibodies suffer from 
the limitation of missing clinically important CTCs 
with low EpCAM expression such as mesenchymal 
and stem cell-like tumor cells. Furthermore, 
immunoaffinity-based isolation methods require a 
relatively long processing time to achieve an efficient 
antigen–antibody interaction [19, 20]. Alternatively, 
marker-independent approaches, based on intrinsic 
physical properties of CTCs, have been developed [21, 
22], but they tend to show lower capture yields and 
purity, and sample pretreatment requirements or 
clogging issues are often a problem. Size-based CTCs 
isolation methods using inertial microfluidics provide 
relatively high detection rates but require prior 
sample preparation steps such as removal of red 
blood cells and dilution [23, 24]. While most of the 
current CTC enumeration technologies rely on signal 
averaging across individual heterogeneous CTCs, 
facile analysis of CTCs at a single-cell resolution is 
highly desired to assess the cell heterogeneity and 
uncover its clinical consequences. Although much 
progress has been made and clinical significance of 
CTCs has been demonstrated, the remaining 
challenges include a high cost, low throughput, and 
complexity of the process, as well as 
false-positive/false-negative results, which hinder a 
wider adoption of CTC-based liquid biopsy as a 
routine practice in clinical settings.  
In this report, we present the preclinical 
validation of a fluid-assisted separation technology 
(FAST) disc [25], which allows rapid (>3 mL/min), 
reproducible, and label-free isolation of CTCs directly 
from unprocessed whole blood of patients with 
NSCLC. We performed serial monitoring of CTC 
counts, mutation detection, and single-cell multiplex 
gene expression of CTCs from a prospective cohort of 
patients with NSCLC receiving EGFR-TKIs treatment. 
The study highlights the potential of a CTC-based 
liquid biopsy for assessing the efficacy of therapy and 
emergent drug resistance. 
Methods 
Study design and blood sample collection 
The biospecimens and data used in this study 
were provided by the Biobank of the Pusan National 
University Hospital (PNUH), a member of the Korea 
Biobank Network. The study protocol was reviewed 
and approved by the Institutional Review Board (IRB) 
of PNUH (H1612-019-049). This was a prospective, 
single-center study conducted at PNUH (Busan, 
Republic of Korea). Patients who met the following 
inclusion criteria were selected for the study: 1) a 
histologically or cytologically confirmed diagnosis of 
primary NSCLC; 2) a confirmed EGFR mutation in 
histological or cytological specimens; 3) previously 
untreated stage IIIB or IV according to the 7th edition 
of TNM staging system by the international 
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association for the study of lung cancer [measurable 
disease according to Response Evaluation Criteria in 
Solid Tumors version 1.1 (RECIST 1.1)]; and 4) 
received at least one dose of EGFR-TKIs as the 
first-line therapy during the follow-up study. Blood 
samples were collected for analysis within 3 days 
before/after EGFR-TKIs treatment. Written informed 
consent was obtained from all patients before blood 
sampling.  
To monitor CTC counts during TKI therapy, 
blood samples were collected from 40 enrolled 
patients on a regular schedule. Peripheral blood (3 
mL) was collected in a Vacutainer® (K2 EDTA, 
#367844; BD Medical) and CTC isolation was 
completed within 6 h [26-28]. For the detection of 
EGFR mutations and single-cell-level gene expression 
analysis, additional 3 mL blood samples were 
collected from 16 patients. For serial monitoring of 
single-cell RNA expression in CTCs, blood samples 
were collected from 75-year-old male (LP25) and 
74-year-old female (LP38) patients diagnosed with 
19del and L861Q EGFR mutant-positive lung cancer, 
respectively, who were receiving afatinib treatment.  
Cell culture 
Breast cancer (MCF7, MDA-MB-231, and 
SKBR3), prostate cancer (LNCaP and PC3), and lung 
cancer (H460, H2228, HCC78, and PC9) cell lines were 
purchased from the American Type Culture 
Collection. All cell lines were cultured in RPMI 1640 
medium supplemented with 5% FBS and 1% 
antibiotics/antimycotics at 37°C, 5% CO2. The 
mycoplasma test was confirmed by e-MycoTM 
Mycoplasma detection kit (Intron, Korea). 
Immunofluorescent staining and analysis of 
CTCs  
Immunofluorescent staining and detection were 
performed on the FAST disc membrane according to a 
previously reported protocol [25]. Briefly, CTCs 
captured on a FAST disc were fixed with 4% 
formaldehyde and permeabilized with 0.1% Triton 
X-100, followed by washing and blocking with 10 
µg/mL IgG in PBS. Cells were identified using a 
three-color immunofluorescence method, including 
FITC-conjugated anti-cytokeratin (CK) and 
anti-EpCAM markers for epithelial cells, a 
PE-conjugated anti-CD45 marker for white blood cells 
(WBCs), and DAPI for nuclear staining. Cells that 
were CK+ or EpCAM+, CD45−, DAPI+, and 
morphologically intact were identified as CTCs, while 
cells that exhibited high CD45 expression levels were 
identified as WBCs. Fluorescently stained cells were 
automatically scanned on a slide using a BioView 
workstation (BioView, Inc.) for the FAST disc. 
CTC isolation and analysis using CellSearch 
CTC enumeration, immunofluorescent staining, 
and detection by the CellSearch epithelial cell test 
(Menarini Silicon Biosystems, Inc.) were performed 
using the CellSearch™ protocol (www.cellsearchctc 
.com) at the Brigham and Women's Hospital (BWH), 
Boston, MA (The BWH IRB number is 2016P001708). 
A FAST disc operation system was shipped to BWH 
and used for a direct comparison with CellSearch. 
Two blood samples were collected from 17 enrolled 
patients with cancer into two types of tubes: 7.5 mL of 
whole blood in CellSave tubes (Menarini Silicon 
Biosystems, Inc.) for CellSearch and 3 mL of whole 
blood in EDTA tubes for FAST disc detection. The 
enumeration of CTCs was performed using the 
recommended protocols for each method, as 
described previously [25, 29, 30]. 
DNA mutation analysis 
To detect mutations in isolated CTCs, genomic 
DNA was extracted using the QIAamp DNA blood 
mini kit (Qiagen). For the detection of L858R, 19del 
and T790M mutations in gDNA, PCR was performed 
using the following cycling conditions on a Master 
cycler pro S instrument (Eppendorf): 95 °C for 10 min, 
followed by 40 cycles of 95 °C for 30 s and 58 °C for 1 
min, and 98 °C for 10min, then held at 4 °C. The PCR 
mixture (20 µL) contained 10 µL of ddPCR supermix 
for probes, no UTP (Bio-Rad), 1 µL of 20× 
primer/probe assay for mutant and wild type 
(Bio-Rad), and 8 µL of DNA. The copy number of 
mutants was quantified using QuantaSoft software 
(Bio-Rad). 
Statistical analysis of CTC enumeration data 
Overall survival (OS) and progression-free 
survival (PFS) were chosen as the endpoints to 
evaluate the prognostic value of CTC counts. The 
survival time was estimated using the Kaplan–Meier 
method, and the difference in survival between 
groups was assessed using a log-rank test. The SPSS 
22.0 for Windows software was used for statistical 
analyses. To confirm the correlation between the CTC 
count change ratio; ∆CTC (%) =  𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖−𝐶𝐶𝐶𝐶𝐶𝐶0
𝐶𝐶𝐶𝐶𝐶𝐶0
× 100 % 
where CTCi is the CTC count at time point i and CTC0 
is the baseline CTC count and imaging response 
results, a two-tailed Student’s t-test with a 95% 
confidence interval was performed using Origin 2015 
(OriginLab Corp.). P-values < 0.05 were considered 
statistically significant. 
Single-cell isolation and multiple gene 
expression analysis 
Single cells were isolated using Kuiqpick™ 
(NeuroInDx). Cells captured on the membrane were 
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stained for CD45, EpCAM, and DAPI to identify 
target cells. Single-cell cDNA was prepared using the 
Single Cell-to-Ct kit (Life Technologies), and a specific 
target was preamplified for gene expression analysis. 
qRT-PCR was performed using a BioMarkHD 
real-time PCR system and the software (Fluidigm). 
For analysis, quality thresholds of 0.65 and Ct ≤ 30 
were considered.  
Undetected genes were assigned a Ct-value of 
999, which was imputed as the highest Ct-value 
observed for a given gene plus a value of 1 to provide 
balanced weights to missing data. All imputed 
Ct-values were converted to Z-scores to provide the 
same weights [31]. To assign equal weights to all 
measured mRNAs, the gene expression values were 
mean-centered and Z score-transformed by dividing 
the mean-centered expression value by the standard 
deviation. We conducted unsupervised hierarchical 
clustering and t-distributed stochastic neighbor 
embedding (t-SNE) to explore associations among 
sample groups. Unsupervised hierarchical clustering 
and its heatmap visualization were performed using 
the heatmap.2 function of the gplots package, and 
t-SNE analysis was performed using the Rtsne 
package in R (version 3.4.0). 
Correlation matrix plots were constructed using 
the corrplot function in R. Correlation matrices were 
computed separately for patient-derived CTCs, cancer 
cell lines, and WBCs, with Spearman’s rank 
correlations. Associated P-values were computed 
using the cor.mtest function in R. The Bonferroni 
correction of P-values was performed to adjust for 
multiple testing in the rank correlation matrix.  
CTC classification 
Based on the gene expression profiling data for 
individual cells, we calculated their epithelial (E) or 
mesenchymal (M) scores. Epithelial markers such as 
EpCAM and CK markers (KRT7, KRT18, and KRT19) 
were selected to measure scores related to epithelial 
characteristics of CTCs. The mesenchymal markers 
vimentin and CD44 were selected to calculate 
M-scores of CTCs. The mRNA expression values of 
the target markers, normalized to those of GAPDH 
using the 2−ΔCt method, were added up for each E/M 
group, and the relative percentage was used to 
classify CTCs according to their epithelial-to- 
mesenchymal transition (EMT) characteristics. 
Results 
Label-free isolation of CTCs from whole blood 
using FAST disc 
A FAST disc is a centrifugal microfluidic device, 
which enables clog-free, label-free CTC isolation from 
whole blood [25] (Figure 1A). In a FAST disc, the fluid 
flow by centrifugal force and that by filtration 
through the membrane are in perpendicular 
directions, similar to the tangential-flow filtration, 
which minimizes clogging (Figure 1B). The operation 
of the FAST disc is very simple and fast: 1) add 3 mL 
of whole blood to the sample-loading chamber; 2) 
spin the disc using a tabletop-sized, portable spinning 
machine; and 3) add 1 mL of washing buffer and spin. 
The total process of the isolation of CTCs from 3 mL of 
whole blood could be finished within 1 minute 
(Figure 1C and Movie S1). The CTC enumeration was 
performed using the conventional criteria for CTC 
identification, EpCAM/CK+ and CD45−, with 
immunofluorescence staining performed on the disc 
(Figure 1D and Figure S1). 
Compared with a commercially available 
product, the CellSearch system (Menarini Silicon 
Biosystems, Inc.), the FAST disc showed a high 
capture efficiency, irrespective of the EpCAM 
expression levels in the cell lines, while CellSearch 
showed a high capture efficiency only for cell lines 
with high EpCAM expression (Figure 1E). Further, 
clinical tests using blood samples from 17 patients 
with various cancer types demonstrated that 
size-selective CTC isolation using the FAST disc 
outperformed the immunoaffinity-based enumeration 
by CellSearch; the detection rates were 94.1% and 
11.8%, respectively. In addition, the failure rates were 
much lower for the FAST disc than for CellSearch, 
5.9% and 23.5%, respectively (Figure 1F). 
Measurement of CTCs in two blood samples collected 
from the same patient confirmed a good 
reproducibility of the FAST disc platform, which is a 
prerequisite for continuous monitoring of the disease 
status (Figure 1G). 
Clinical characteristics of the prospective 
cohort of patients with NSCLC receiving 
EGFR-TKIs treatment 
A total of 340 blood samples were obtained from 
40 patients diagnosed with NSCLC with EGFR 
mutations at different treatment time points for CTC 
isolation using the FAST disc platform; a summary of 
the patients’ baseline characteristics is shown in Table 
1. At the time of analysis, 22 of the 40 patients (55.0%) 
experienced disease progression, and 12 patients 
(30.0%) died or were lost to follow-up, resulting in a 
median PFS of 13.1 months (95% CI: 11.7‒16.3 
months) and OS of 19.0 months (95% CI: 15.6‒20.2 
months). The average follow-up time for the 28 
patients who were still alive was 19.6 months (range: 
9.8‒31.3 months). 
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Figure 1. Workflow, mechanism, and performance of FAST disc. (A) Visualization of the FAST disc before and after the CTC enumeration process. (B) The centrifugal 
force pushes the liquid in a tangential direction to the flow filtering through the membrane. (C) Size-based isolation of CTCs from whole blood (3 mL) can be completed within 
1 min, all in one disc. After washing and staining for enumeration, the filter can be removed and mounted on a slide glass for downstream analysis. (D) Representative images of 
CTCs (DAPI+, EpCAM/CK+, CD45-) isolated from the blood of cancer patients. (E) Performance comparison between the CellSearch system and FAST disc using whole blood 
spiked with cancer cells (<100). Five cell lines with various EpCAM expression levels were used to quantify the recovery rates. (F) CTCs enumerated by the CellSearch system 
and FAST disc from the blood samples of 17 patients with different cancer types. (G) Reproducibility test using blood samples from one patient collected in two independent 
blood collection tubes showing similar CTC counts. 
 
Table 1. Patients demographics and clinical characteristics 
Characteristics No. (%) 
Age at baseline, years  
Median 63 
range 34-83 
Sex  
Male 15 (37.5) 
Female 25 (62.5) 
M stage at diagnosis  
M0 3 (7.5) 
M1a 6 (15) 
M1b 31 (77.5) 
EGFR mutation  
19del 19 (47.5) 
L858R 16 (40) 
Others 5 (12.5) 
EGFR-TKI received  
Gefitinib 2 (5) 
Erlotinib 9 (22.5) 
Afatinib 29 (72.5) 
 
Baseline CTC counts and survival 
The median CTC0 value among 38 tested patients 
was 37 CTCs/7.5 mL. With the cutoff value of 66 
CTCs/7.5 mL, which minimized the p-value from the 
log-rank test, eight patients (21.1%) showed CTC 
counts higher than the cutoff (CTCHigh group). Thirty 
patients (78.9%) showed CTC counts lower than the 
cutoff (CTCLow group). As shown in Figure S2A, the 
CTCLow group had a relatively longer OS than did the 
CTCHigh group, but the difference was not statistically 
significant. Thus, no correlation was observed 
between CTC0 and OS. One possible reason is that the 
efficacy of the first-line therapy, rather than CTC0 
itself, might be more relevant to OS of the prospective 
cohort of patients tested in this study (Figure S2B-C). 
Serial monitoring of CTC counts 
We next focused on the trends of CTC counts to 
evaluate the correlation with patients’ disease burden 
and treatment response, as shown in Figure 2. A 
cohort of 11 patients who had the 19del mutation and 
were enrolled for more than 19 months was used to 
evaluate the correlation of CTC counts with the 
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treatment response. The RECIST criteria (version 1.1) 
were used to assess the treatment response via 
computed tomography (CT) scans acquired every two 
or three cycles, and responses were classified as a 
complete response (CR), partial response (PR), stable 
disease (SD), or progressive disease (PD) [32]. When 
we compared the change rate of the CTC counts as a 
function of the imaging response results, the PD 
group (average 70.1% increase, N=17) showed a 
significantly higher CTC count change rate than did 
the PR group (average 43.1% decrease, N=24). 
Detection of EGFR mutations in tumor tissue 
and CTCs isolated using the FAST disc 
We evaluated the concordance rate in detecting 
mutations in tumor tissue and CTCs isolated from 
blood samples. In 15 samples from 13 patients, the 
mutations identified in CTCs were 100% consistent 
with those found in the matching tumor tissues. 
Interestingly, the EGFR T790M mutation was detected 
in both relapsed tissue and CTCs isolated from blood 
samples of two patients, LP2 and LP49, who did not 
show this mutation during their first biopsy using 
both tumor tissue and blood samples, as summarized 
in Table 2. 
 
Table 2. Detection of EGFR mutation from CTCs. The 
mutation detection results from CTCs isolated from total 13 
patients were in 100% concordance with the corresponding 
results obtained from tissue biopsy sample. Notably, T790M, the 
acquired resistance EGFR mutation, detected at relapse (AR) of 
samples, but not before the treatment (BT), from two patients 
(LP49 and LP2) both from noninvasive blood-based CTC analysis 
as well as tumor biopsy. 
Patient Sex Age Stage L858R T790M 
Tissue CTC Tissue CTC 
LP1 F 52 IV + + - - 
LP5 M 49 IV + + - - 
LP6 M 58 IV + + - - 
LP8 F 76 IV + + - - 
LP10 M 63 IV + + - - 
LP12 F 90 IV + + - - 
LP13 F 53 IV + + - - 
LP46 F 67 IV + + - - 
LP47 F 83 IV + + - - 
LP49 (BT) F 65 IIIA + + - - 
LP49 (AR) F 65 IIIA + + + + 
Patient Sex Age Stage 19 del T790M 
Tissue CTC Tissue CTC 
LP2 (BT) M 53 IV + + - - 
LP2 (AR) M 53 IV + + + + 
LP25 M 74 IV + + - - 
LP43 F 59 IV + + - - 
 100% 100% 
 
 
 
Figure 2. Representative examples of CTC counts and CT images obtained during the course of treatment and their correlations. (A) Tumor size and CTC 
counts show an increase in the tumor burden during 582 days of various EGFR-TKI treatments for patient LP2. (B) Patient LP11 continued to receive erlotinib initially. The CTC 
counts from the blood draw at 301 and 378 days were significantly increased with PD determined from CT images obtained on days 294 and 378. After the treatment was 
changed to alimta, both the CTC counts and tumor burden decreased dramatically and PR was determined at day 462. (C) Relationships with the change rate of CTC counts, 
△CTC (%); CTC counts change normalized by the baseline CTC, and CT scan image response results from patients with a 19 del mutation who enrolled in the follow-up 
monitoring study for more than 19 months. The CTC count change rate is sorted according to the imaging response results (PD or PR). The PD group showed a significantly 
greater CTC count change rate than the PR group (P = 0.011). 
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Single-cell RNA expression analysis of 
patient-derived CTCs 
To characterize the tumor heterogeneity, we 
applied a single-cell manipulation technique to isolate 
patient-derived live CTCs. After blood filtration and 
immunostaining for CD45 without a fixation step, live 
CTCs captured on the membrane were collected, and 
individual cells without a CD45 signal were subjected 
to single-cell RNA expression analysis (Figure S3 and 
Figure 3). 
We assessed mRNA expression in individual 
cells isolated from the four lung cancer cell lines, 
H2228, H460, HCC78, and PC9 (Figure S4), and from 
the blood samples withdrawn from three patients 
with NSCLC, LP25, LP38, and LP39, before starting 
their EGFR-TKIs therapy, using WBCs as a control 
(Figure S5). Differences in the gene expression were 
confirmed between the cell lines, and CD45 was only 
detected in WBCs. The list of genes used in the 
single-cell qRT-PCR experiment is presented in Table 
S1. To explore associations among different cell 
groups, the data were analyzed using unsupervised 
hierarchical clustering (Figure 3A). It is obvious that 
individual cells show heterogeneous gene expression 
profiles, while single cells from the same group are 
clustered together, which implies a higher degree of 
interpatient heterogeneity of CTCs. In addition, the 
t-SNE analysis, shown in Figure 3B, clearly presents 
the inter-cell line and interpatient heterogeneity of 
CTCs. A correlation matrix plot showing Spearman’s 
correlation coefficient among 30 baseline CTCs 
isolated from three patients, five WBCs, and 20 cells 
from the four different NSCLC cell lines (H2228, 
H460, HCC78, and PC9) is shown in Figure S6. 
We further characterized an epithelial or 
mesenchymal signature of individual CTCs, based on 
previous reports [33-35]. Epithelial CTCs showed high 
levels of the epithelial marker EpCAM and CK 
markers, KRT7, KRT18, and KRT19, and low levels of 
mesenchymal markers, vimentin and CD44, whereas 
mesenchymal CTCs expressed the opposite trend. 
Individual cells from the four different NSCLC cell 
lines and three different patients with NSCLC showed 
different E/M hybrid signatures (Figure 3C and 
Figure S7A). Based on the classification criteria, the 
H2228 cell line had an M-score of 66.0% ± 0.7%, which 
was consistent with its reported EMT properties [36]. 
The HCC78 and PC9 cell lines had the highest 
expression ratios of the epithelial markers, 95.2% ± 
6.3% and 85.0% ± 2.9%, respectively. The H460 cell 
line had an intermediate expression ratio, with an 
M-score of 52.2% ± 8.5%. Despite their heterogeneity, 
single cells from the same cell lines were clustered 
together when we plotted the gene expression of the 
mesenchymal markers, vimentin and CD44, against 
that of the epithelial markers, EpCAM, KRT7, KRT18, 
and KRT19 (Figure S8). 
Further, distinct differences in gene expression 
patterns among single CTCs from the three patients 
were clearly more significant than the heterogeneity 
found among individual CTCs isolated from each 
patient. Five CTCs from patient LP25 mainly 
exhibited the epithelial signature, whereas seven 
CTCs from patient LP38 were mesenchymal. On the 
other hand, 18 CTCs from patient LP39 were more 
heterogeneous, with the intermediate expression of 
mesenchymal markers (Figure 3C and Figure S7A). 
High expression of EMT markers is known to be 
characteristic of more aggressive CTCs [37]. Although 
the number of samples was very limited in this 
exploratory study, patient LP38, whose CTCs showed 
the highest mesenchymal gene expression, had the 
shortest survival, whereas patient LP25, whose CTCs 
mainly showed epithelial characteristics, had the 
longest survival. The survival periods of patients 
LP25, LP38, and LP39 were 624, 212, and 468 days, 
respectively. 
Serial monitoring of single-cell RNA 
expression in CTCs from patients with NSCLC 
during EGFR-TKI treatment 
For treatment response monitoring using CTCs, 
we performed a single-cell-level mRNA gene 
expression analysis using individual CTCs isolated at 
three time points during chemotherapy, in addition to 
regular measurements of CTC counts and CT image 
responses. For this proof of concept study, we 
enrolled two prospective patients, LP25 (Figure 4) 
and LP38 (Figure 5), during the period of EGFR-TKI 
(afatinib) treatment. 
In the case of patient LP25, the initial treatment 
response was relatively good, and the number of 
CTCs/7.5 mL of blood decreased from 57.5 at baseline 
to 2.5 after 159 days of treatment, which was 
consistent with the CT scan-based SD and PR statuses 
after 30, 90, and 180 days of treatment, as shown in 
Figure 4A. However, the CTC counts increased to 
15.0, 67.5, and 195.0 per 7.5 mL after 187, 250, and 281 
days of treatment, which was in good agreement with 
radiographic data, indicating PD, at 282 days of 
treatment. 
In contrast, patient LP38 showed 67.5 CTCs/7.5 
mL at baseline, but the counts decreased to 12.5, 25.0, 
5.0, and 15.0 at 71, 120, 155, and 196 days of treatment, 
respectively. Although the patient initially showed an 
SD response, until 120 days of treatment, the tumor 
size increased again, scoring PD, at 196 days, and the 
patient died 211 days after entering the study. 
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Although the dynamic changes in the numbers 
of CTCs were overall consistent with the CT data and 
clinical outcomes, the CTC counts were not sufficient 
to predict clinical outcomes. We hypothesized that, in 
addition to the total number of CTCs, the 
heterogeneity of individual CTCs and their 
characteristics might affect the patient outcome. 
Therefore, we tracked the gene expression 
characteristics of individual CTCs during the time 
course of TKI therapy. 
For patient LP25, the single-cell-level gene 
expression profiling was performed using 5, 17, and 
20 CTCs isolated before (LP25-0), after 250 days 
(LP25-8), and after 281 days (LP25-9) of treatment, 
respectively (Figure 4 and Figure S9). From patient 
LP38, 7, 17, and 22 CTCs were isolated before 
(LP38-0), after 120 days (LP38-3), and after 155 days 
(LP38-4) of treatment, respectively (Figure 5 and 
Figure S10). The numbers of CTCs used for the gene 
expression analysis (Figure 4B–D and Figure 5B–D) 
did not reflect the total numbers of CTCs, which were 
more carefully enumerated using an additional blood 
sample, as shown in Figure 4A and Figure 5A. As 
shown in the 3D t-SNE plots in Figure 4C and Figure 
 
 
Figure 3. Gene expression profiles of single CTCs isolated from three patients with lung cancer and from lung cancer cell lines. (A) Heat map for the 
hierarchical clustering of the differentially expressed genes of single cells from four different NSCLC cell lines [H2228 (orange), H460 (purple), HCC78 (brown), and PC9 
(green)], WBCs (black), and CTCs from three patients [LP25 (red), LP38 (blue), and LP39 (cyan)]. Each row represents a single-cell sample. The scale bar indicates the Z-scores 
of gene expression values, with highly expressed genes depicted in red and low-expressed genes depicted in green. (B) Two-dimensional t-SNE analysis based on hierarchical 
clustering. Cells clearly grouped according to the sample source. (C) Gene expression data of individual cells were further characterized to show an epithelial or mesenchymal 
cell signature. Intra- and intercellular heterogeneity is demonstrated using four different NSCLC cell lines, and profiling of individual CTCs isolated from three patients with 
NSCLC patients before chemotherapy. Patients LP25 and LP39 carried an 19del mutation, and patient LP38 had the L861Q mutation. 
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5C, each individual CTC showed a different gene 
expression pattern in hierarchical clustering, but 
CTCs from the same time point were well clustered 
together for both patients. In addition, the gene 
expression profiles of CTCs isolated at different time 
points were distinctly different, which was also 
demonstrated by the correlation matrix analysis 
(Figure S11 and Figure S12). 
We further characterized the EMT signatures of 
individual CTCs isolated during the time course of 
therapy. As shown in Figure 4A, patient LP25 showed 
SD and PR based on the CT scan results until 180 
days, but the status changed to PD because of a new 
brain lesion at 282 days (LP25-9). Interestingly, the 
LP25-9 CTCs showed much higher expression of 
many more genes than did the LP25-0 or LP25-8 
 
 
Figure 4. Longitudinal study of LP25 with CTC counts, individual CTC profile, and CT image response during TKI therapy. (A) Correlation between the 
number of CTCs and tumor size from CT images in patient LP25 with EGFR-mutant NSCLC during the course of TKI therapy. (B) Heatmap of the hierarchical clustering of gene 
expression profiles of single CTCs. (C) Three-dimensional t-SNE plots for CTCs isolated at three time points during the therapy of patient LP25. Despite the inter-sample 
heterogeneity of CTCs, cells clustered according to the same time point during the treatment. (D) EMT characterization of single CTCs from patient LP25 during TKI treatment. 
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CTCs. When we classified individual CTCs based on 
the epithelial or mesenchymal gene expression 
signature, the heterogeneity of individual CTCs, as 
well as the dynamic change of the M-score, was 
obvious, as shown in Figure 4D. The M-score of CTCs 
at baseline (LP25-0) was relatively low (22.06% ± 
12.96%) but increased, with a large standard deviation 
(49.53% ± 24.80%), for CTCs isolated after 250 days 
(LP25-8), which was approximately 1 month before 
PD was scored, with a new lesion in the brain. 
Interestingly, CTCs obtained on day 282, which was 
when a CT scan was taken, and PD was scored 
(LP25-9), showed a slightly decreased M-score, with a 
much lower intra-sample heterogeneity (37.51% ± 
4.96%; Figure S7B). 
 
 
Figure 5. Longitudinal study of patient LP38 with CTC counts, individual CTC profile, and CT image response during TKI therapy. (A) Correlation between 
the number of CTCs and tumor size from CT images in patient LP38 with EGFR-mutant NSCLC during the course of TKI therapy. (B) Heatmap of the hierarchical clustering of 
gene expression profiles of single CTCs. (C) Three-dimensional t-SNE plots for CTCs isolated at three time points during the therapy of patient LP38. Despite the inter-sample 
heterogeneity of CTCs, the cells clustered according to the same time point during the treatment. (D) EMT characterization of single CTCs from patient LP38 during TKI 
treatment. 
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Patient LP38 had the highest expression of many 
genes in baseline CTCs (LP38-0), which somewhat 
decreased in CTCs isolated after 120 days of treatment 
(LP38-3), but with a significantly enhanced 
heterogeneity (Figure 5D and Figure S7C). Likewise, 
the tumor size was the largest at LP38-0 and 
decreased by 22% as the target lesion was scored SD 
(LP38-3). However, CTCs isolated after 155 days of 
treatment (LP38-4) again showed increased gene 
expression signals, which was consistent with the 
future clinical outcome and a PD score after 196 days 
of treatment. The EMT signature of individual CTCs 
was the strongest (82.39% ± 4.61%) at baseline 
(LP38-0), which dramatically decreased, with a high 
heterogeneity (39.24% ± 18.30%), in the LP38-3 CTCs 
and then remained at a similar level but with a lower 
heterogeneity (42.09% ± 8.31%) in the LP38-4 CTCs. 
Unfortunately, the amount of the blood sample 
obtained on day 196 was not sufficient for single-cell 
analysis, and the patient expired after 15 days. 
Discussion 
The availability of more facile methods for 
measuring the disease progression and identifying 
predictive biomarkers of therapeutic responses in 
patients with NSCLC would significantly contribute 
to clinical outcomes of patients. Recent advances in 
liquid biopsy technologies have enabled less invasive 
access to tumor materials, highlighting the prognostic 
value of CTCs in disease management [38-42]. 
However, frequent monitoring of CTCs has been 
limited by inconsistency in the enrichment yield of the 
extremely rare and heterogeneous cells, as well as by 
high costs and complexity of experimental protocols. 
Our study of prospectively collected blood samples 
from patients with NSCLC before and during 
EGFR-TKI therapy showed that longitudinal analysis 
of CTCs enumerated using a label-free isolation 
approach might provide early access to monitoring 
disease responses to targeted therapy. 
Many studies have demonstrated that 
pretreatment CTC counts are highly relevant to PFS or 
OS of patients with advanced NSCLC [11, 12]. 
However, there have also been conflicting reports 
showing no statistical significance in the survival 
outcome depending on baseline CTC counts [17, 18]. 
A likely explanation for this discrepancy is the lack of 
standard enumeration methods for extremely rare 
and heterogeneous CTCs, as well as differences in the 
type of patients and the choice of treatment options. 
In our study, CTCs were detected in the majority of 
patients (85%), but the baseline CTC counts did not 
show an association with PFS or OS. On the other 
hand, dynamic changes in CTC counts were 
associated with CT scan-based tumor responses, 
suggesting a potential utility for early identification of 
responses to therapies. Although our data are 
consistent with those of a previous report [43], the 
number of patients was limited, and a further study, 
with a larger number of prospective patients in a 
setting with other targeted therapies or 
chemotherapy, is required to validate these findings. 
Frequent monitoring of tumor mutations in 
patients with lung cancer is an urgent need to provide 
a clinically important guidance for disease 
management [44-47]. For most patients with NSCLC, 
who harbor EGFR mutations, the treatment with an 
EGFR-TKIs therapy is beneficial. However, the T790M 
point mutation may arise soon, indicating the 
development of resistance to EGFR-TKI and the 
necessity to change the drug to third-generation 
EGFR-TKIs. Tissue biopsy is highly invasive, which 
prevents frequent monitoring of the development of 
mutations, and may not provide a representative 
mutation profile for patients with heterogeneous 
tumors at multiple sites. In this study, we 
demonstrated 100% concordance in the detection of 
EGFR mutations in tumor tissue and CTCs isolated 
from a total of 15 samples collected from 13 patients, 
including two cases of the emergence of the T790M 
mutation. These results present a promising outlook 
on the potential of routine analysis of CTCs to provide 
clinically relevant information for the timely selection 
of personalized therapies. 
Other molecular information, such as gene 
expression data, can also be obtained by downstream 
analysis of a single CTC. Direct analysis of bulk cells 
may generate background signals from WBCs and 
other blood cells [48]. Furthermore, bulk cell-level 
analysis, based on signal averaging, leads to losing 
individual characteristics of heterogeneous CTCs, 
which are related to tumor biology and metastatic 
potential [49]. The importance of CTC 
characterization at a single-cell level has been 
highlighted by profiling multigene expression in 
individual CTCs in a heterogeneous population [19, 
46], classifying CTC subpopulations [31], and 
studying an association of CTCs with the clinical 
outcome or tumor biology [50]. Herein, by using a 
label-free, high-throughput, clinical setting-friendly 
method for CTC isolation, based on the previously 
reported tabletop-sized FAST disc system [25], we 
were able to perform a longitudinal analysis of 
single-cell gene expression in CTCs isolated before 
and during targeted therapy. Our findings from 
single-cell gene expression analysis of four different 
lung cancer cell lines and three different patients 
indicated that the inter-heterogeneity among different 
cell lines or patients was much higher than the 
intra-heterogeneity within each group of CTCs. 
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EMT plays a key role in tumor progression and 
metastasis. EMT is associated with the loss of the 
epithelial phenotype, and increased invasion, 
migration, and cell proliferation are associated with 
the increased expression of mesenchymal markers. A 
number of studies have suggested that EMT may be 
associated with the resistance to EGFR-TKIs in 
patients with NSCLC [51, 52]. It was also suggested, 
based on liquid biopsy applications, that CTCs 
expressing EMT-related genes were associated with 
the disease progression and poor therapeutic 
responses in patients with breast [33], gastric [34], 
pancreatic [31], and lung [53] cancer. Gene expression 
in single cells has been studied to evaluate the 
heterogeneity of individual CTCs. Thus, Lin et al. [35] 
characterized single CTCs and demonstrated their 
inter- and intra- patient heterogeneity in four patients 
with pancreatic cancer. Ting et al. [54] conducted 
single-cell RNA sequencing of pancreatic CTCs and 
identified three distinct populations, with the data 
suggesting multiple pathways in the metastatic 
cascade. However, molecular analysis of single CTCs 
remains challenging because currently available 
platforms are expensive and not robust enough to be 
translated into the clinic. Consequently, there have 
been no reports on longitudinal monitoring of 
therapeutic responses via profiling of the EMT 
signature in individual CTCs based on a single-cell 
gene expression analysis. 
EMT is crucial for cancer cells to acquire invasive 
and migratory abilities, eventually driving tumor 
metastasis. Recent studies have reported that EMT is 
not a step function, in which the change occurs from 
the E to the M state and that cells rather exhibit a 
hybrid E/M phenotype with a mix of E/M traits, 
which may be highly correlated with patient 
outcomes [52, 55, 56]. One important result of this 
study was that the E/M signature scores obtained by 
multigene expression analysis of single cells revealed 
substantial heterogeneity among individual cells and 
among cell lines. Despite their relatively small 
intra-heterogeneity, the EMT scores of individual cells 
from four different NSCLC cell lines could predict the 
known characteristics of the specific cell types, which 
were categorized as mainly mesenchymal or 
epithelial, or a hybrid state, showing both traits [52, 
57, 58]. Furthermore, analysis of EMT scores of 
individual pretreatment CTCs isolated from three 
patients with NSCLC indicated that the patients who 
showed relatively poor drug responses had CTCs 
with high M-scores, while the patient who showed a 
relatively good response to EGFR-TKI therapy had 
CTCs with high E-scores. Despite the heterogeneity in 
multigene expression and EMT scores among CTCs 
isolated from the patients, CTCs from the same source 
were clustered together, suggesting that the 
interpatient heterogeneity was higher than the 
intra-patient one. 
We also monitored how multigene expression 
and EMT signatures evolved during EGFR-TKI 
therapy. Based on the data obtained using a limited 
number of CTCs isolated from two patients, the EMT 
scores of pretreatment CTCs were better associated 
with the drug response than were those of CTCs 
obtained during EGFR-TKI therapy. Even though the 
EMT scores of pretreatment CTCs were distinctly 
different (predominantly E or M), the EMT signatures 
of individual CTCs became more heterogeneous and 
then changed to a relatively uniform E/M hybrid 
signature during EGFR-TKI treatment. However, the 
meaning of the change in multigene expression 
profiles should be further validated in relation to drug 
responses in future studies, involving large cohorts of 
patients.  
Although we only performed gene expression 
analysis using the Fluidigm technology, CTCs 
isolated without antibody selection bias can be 
applied for other types of molecular analysis at a 
single-cell level to unveil the tumor heterogeneity 
during disease progression upon personalized 
therapy. Despite the significantly reduced turnaround 
time and minimized manual operation steps, the CTC 
counting and picking process still require manual 
operation, which need to be automated for broader 
usage in clinical settings. A potentially important 
application of our technology is the isolation of CTC 
clusters, which are emerging as important players in 
metastasis. Though we could frequently observe CTC 
clusters from patients with other types of cancer, CTC 
clusters were rarely observed from patients with 
NSCLC (Figure S1B). In recent studies on inertial 
microfluidics-based CTC isolation using blood 
samples from patients with NSCLC, Zhou et al. did 
not observe CTC clusters [23], while Zeinali et al. 
detected CTC clusters from the majority of patients 
[24]. We believe that this discrepancy might be due to 
the different cohort of patients with relatively limited 
number of clinical samples. 
In conclusion, we demonstrated that the 
label-free and clinical setting-friendly FAST disc 
platform enabled rapid enumeration of CTCs and 
their unbiased molecular analysis at a single-cell level. 
Our approach can be readily applied in future clinical 
studies for early detection of actionable mutations for 
therapy selection and disease monitoring. Our 
findings from an exploratory, small-scale, prospective 
cohort study of EGFR-mutant patients with NSCLC 
support the importance of single-cell-level molecular 
analysis, including an EMT signature, to investigate 
the dynamics of disease progression and predict the 
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drug response. We anticipate that the FAST disc 
system can become a clinical research tool to achieve 
comprehensive molecular profiling and assess the 
heterogeneity of CTCs from patients undergoing 
targeted therapy and to monitor the association with 
clinical outcomes. Overall, high-throughput, 
label-free isolation of CTCs from whole blood using 
the FAST disc platform may facilitate minimally 
invasive characterization and frequent monitoring of 
tumor progression for timely selection of a 
personalized medicine.  
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